000			01755 a2200517 4500
005			20250514020102.0
264		0	_c20011213
008			200112s 0 0 eng d
022			_a0041-1337
024	7		_a10.1097/00007890-200111270-00010 _2doi
040			_aNLM _beng _cNLM
100	1		_aBruce, D S
245	0	0	_aMulticenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients. _h[electronic resource]
260			_bTransplantation _cNov 2001
300			_a1637-43 p. _bdigital
500			_aPublication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAntibodies, Monoclonal _xadverse effects
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aDaclizumab
650	0	4	_aFemale
650	0	4	_aGraft Rejection
650	0	4	_aGraft Survival
650	0	4	_aHumans
650	0	4	_aImmunoglobulin G _xadverse effects
650	0	4	_aImmunosuppression Therapy
650	0	4	_aImmunosuppressive Agents _xtherapeutic use
650	0	4	_aKidney Transplantation _xadverse effects
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMycophenolic Acid _xanalogs & derivatives
650	0	4	_aPancreas Transplantation _xadverse effects
650	0	4	_aRetrospective Studies
650	0	4	_aSurvival Rate
650	0	4	_aTacrolimus _xtherapeutic use
700	1		_aSollinger, H W
700	1		_aHumar, A
700	1		_aSutherland, D E
700	1		_aLight, J A
700	1		_aKaufman, D B
700	1		_aAlloway, R R
700	1		_aLo, A
700	1		_aStratta, R J
773	0		_tTransplantation _gvol. 72 _gno. 10 _gp. 1637-43
856	4	0	_uhttps://doi.org/10.1097/00007890-200111270-00010 _zAvailable from publisher's website
999			_c11640892 _d11640892